Directors & Officers
| Name | Title | Year Born |
|---|---|---|
| Mr. Sumit Aggarwal M.B.A. | President, CEO & Director | 1973 |
| Mr. Daniel E. Geffken M.B.A. | Interim Chief Financial Officer | 1957 |
| Mr. John Woolford | VP & Head of Corporate Development | NA |
ELOX
Eloxx Pharmaceuticals, Inc.
Employees
10
Phone
781 577 5300
Fiscal year end
December
IPO
Jun 09, 2026
Address
P.O. Box 274, Arlington, MA, United States, 02476
12.92
-0.42 (-3.14%)
USD · NASDAQ
52-week range
8.20
23.40
Trading at 31% of the 52-week range
Market Cap
53.85M
P/E Ratio
3.79
Forward P/E
0.00
Book Value
11.50
Div. Yield
N/A
% Institutions
73.76%
% Insiders
19.07%
1 Year
+21.2%3 Year
+21.2%10 Year
+21.2%Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Actions
Add an action for ELOX.US, or sign in to see your action list.
People
Shareholders
Financial Highlights
Market Cap:
$53.85M
P/E Ratio:
$3.79
Book Value:
$11.50
Earnings/Share:
$3.52
Profit Margin:
0.00%
Operating Margin:
0.00%
ROA (TTM):
0.00%
ROE (TTM):
0.00%
Revenue (TTM):
$0.00
Revenue/Share (TTM):
$0.00
Earnings Growth (YOY):
0.00%
Revenue Growth (YOY):
0.00%
Valuation Metrics
Enterprise Value:
$41.92M
Trailing P/E:
3.79
Forward P/E:
0.00
Shares Statistics
Shares Outstanding:
4.04M
Shares Float:
932.58K
% Insiders:
19.07%
% Institutions:
73.76%
Short % Float:
1.14%
Stock Price History
1 Year Price History
3 Years Price History
10 Years Price History
Max Price History
Financial Charts
Revenue, Net Income & Operating Cash Flow (Yearly)
Change % vs Prior Year
Revenue, Net Income & Operating Cash Flow (Quarterly)
Change % vs Prior Quarter
Operating Expenses (Yearly)
Operating Expenses (Quarterly)
Balance Sheet (Yearly)
Balance Sheet (Quarterly)
Assets Breakdown (Yearly)
Assets Breakdown (Quarterly)
Liabilities Breakdown (Yearly)
Liabilities Breakdown (Quarterly)
Income Statement Waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-3.38M
R&D
adjust
$-3.06M
Operating Income
subtotal
$-6.44M
Other / Non-Operating Items
adjust
$443.00K
Net Income
subtotal
$-6.00M
Earnings Per Share (EPS) History
Financial Ratios
📦 Raw API Data (JSON Explorer)
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.